Mesa Labs returns to profit, names new CEO; China headwinds persist in Clinical Genomics

Filed June 3, 2026 · Period ending March 31, 2026 · Compared to 10-K May 28, 2025 · ~1 min read

Key Changes

• high

  Company returned to profitability with $6.7M net income in FY2026 vs. $2.0M loss prior year; revenues grew 3.4% to $249.1M driven by Sterilization and Disinfection Control segment.

  Notes: Consolidated Financial Results verify on EDGAR →
• high

  Clinical Genomics revenues fell 3.6% due to China macroeconomic weakness and trade tensions; segment now derives ~20% of revenue from a single customer, up from no customer exceeding 10% consolidated previously.

  MD&A: China Headwinds / Risk Factors: Customer Concentration verify on EDGAR →
• high

  Dr. Siddhartha Kadia appointed CEO effective fiscal 2027; company incurred $6.7M in one-time transition costs including $3.7M accelerated stock compensation for departing CEO.

  MD&A: CEO Transition verify on EDGAR →